Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: IRWIN JAMES FRANKEL	9/16/2010 9:22:38 AM
	Read Replies (1) of 3027

Interesting post from IH: genisi Thursday, September 16, 2010 6:48:33 AM Re: RockRat post# 104334 Post # of 104388 In the oligosaccharide characterization territory I don't think Teva has experts like Ganesh Venkataraman and Ram Sasisekharan nor some "hidden magical" IP. I believe what Teva has done and can do is use all known techniques and tools to conducts the analysis. The one thing Roy, Jim and myself once thought could make a difference was when Teva has signed an agreement with Procognia under which Teva gained access to Procognia's proprietary glycoanalysis technology, but after digging there I've posted this isn't a possibility. siliconinvestor.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next